These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38287343)
21. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456 [TBL] [Abstract][Full Text] [Related]
22. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. Ma F; Yang X; Zhou M; Bai M; Zhao L; Li L; Dong R; Liu C; Li R; Sun S J Nephrol; 2020 Dec; 33(6):1241-1250. PubMed ID: 32447619 [TBL] [Abstract][Full Text] [Related]
23. Treatment of IgA nephropathy. Pozzi C J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268 [TBL] [Abstract][Full Text] [Related]
24. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636 [TBL] [Abstract][Full Text] [Related]
25. Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study. Zhao J; Ma F; Bai M; Sun S Clin Ther; 2021 May; 43(5):859-870. PubMed ID: 33863547 [TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. Yang YZ; Chen P; Liu LJ; Cai QQ; Shi SF; Chen YQ; Lv JC; Zhang H BMC Nephrol; 2019 Aug; 20(1):297. PubMed ID: 31382914 [TBL] [Abstract][Full Text] [Related]
27. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children. Kang Z; Li Z; Duan C; Wu T; Xun M; Ding Y; Zhang Y; Zhang L; Yin Y Pediatr Nephrol; 2015 Jul; 30(7):1121-9. PubMed ID: 25773534 [TBL] [Abstract][Full Text] [Related]
28. Reduction in proteinuria after immunosuppressive therapy and long-term kidney outcomes in patients with immunoglobulin A nephropathy. Kang SC; Kim HW; Chang TI; Kang EW; Lim BJ; Park JT; Yoo TH; Jeong HJ; Kang SW; Han SH Korean J Intern Med; 2021 Sep; 36(5):1169-1180. PubMed ID: 33561333 [TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive therapy versus supportive care in IgA nephropathy patients with stage 3 and 4 chronic kidney disease. Ștefan G; Stancu S; Zugravu A; Petre N; Secăreanu S; Popa O; Capusa C Medicine (Baltimore); 2022 Sep; 101(36):e30422. PubMed ID: 36086774 [TBL] [Abstract][Full Text] [Related]
30. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection. Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274 [TBL] [Abstract][Full Text] [Related]
31. Renal outcome after tonsillectomy plus corticosteroid pulse therapy in patients with immunoglobulin A nephropathy: results of a multicenter cohort study. Hoshino J; Fujii T; Usui J; Fujii T; Ohashi K; Takaichi K; Suzuki S; Ubara Y; Yamagata K Clin Exp Nephrol; 2016 Aug; 20(4):618-627. PubMed ID: 26577676 [TBL] [Abstract][Full Text] [Related]
32. Prognostic role of mesangial IgM deposition in IgA nephropathy: a long-term cohort study. Stefan G; Stancu S; Zugravu A; Terinte-Balcan G Ren Fail; 2024 Dec; 46(1):2313179. PubMed ID: 38357771 [TBL] [Abstract][Full Text] [Related]
33. Impact of body mass index on progression of primary immunoglobulin a nephropathy. Nagaraju SP; Rangaswamy D; Mareddy AS; Prasad S; Kaza S; Shenoy S; Saraf K; Attur RP; Parthasarathy R; Kosuru S; Mateti UV; Guddattu V; Koulmane Laxminarayana SL Saudi J Kidney Dis Transpl; 2018; 29(2):318-325. PubMed ID: 29657199 [TBL] [Abstract][Full Text] [Related]
34. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function. Moriyama T; Nakayama K; Ochi A; Amemiya N; Tsuruta Y; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K Clin Exp Nephrol; 2012 Apr; 16(2):231-7. PubMed ID: 22038185 [TBL] [Abstract][Full Text] [Related]
35. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison. Ismail G; Obrişcă B; Jurubiţă R; Andronesi A; Sorohan B; Vornicu A; Sinescu I; Hârza M Medicine (Baltimore); 2020 Jun; 99(26):e21000. PubMed ID: 32590815 [TBL] [Abstract][Full Text] [Related]
36. Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. Coppo R J Am Soc Nephrol; 2017 Jan; 28(1):25-33. PubMed ID: 27671778 [TBL] [Abstract][Full Text] [Related]
37. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121 [TBL] [Abstract][Full Text] [Related]
38. Prognostic role of glomerular electron microscopy lesions in IgA nephropathy: "the devil is in the details". Terinte-Balcan G; Stancu S; Zugravu A; Capusa C; Radu A; Mircescu G; Stefan G J Nephrol; 2023 Nov; 36(8):2233-2243. PubMed ID: 37632668 [TBL] [Abstract][Full Text] [Related]
39. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience. Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961 [TBL] [Abstract][Full Text] [Related]
40. Pro: STOP immunosuppression in IgA nephropathy? Pozzi C Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]